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Abstract This study aimed to synthesize a new
177Lu-iPSMA-RGD heterobivalent radiopharmaceutical, as
well as to assess the in vitro radiopharmaceutical potential
to target cancer cells overexpressing PSMA and a(v) b(3)
integrins. The radiotracer prepared with a radiochemical
purity of 98.8 ± 1.0% showed stability in human serum,
specific recognition with suitable affinity to PSMA and
a(v)b(3) integrins, and capability to inhibit cancer cell
proliferation and VEGF signaling (antiangiogenic effect).
Results warrant further preclinical studies to establish the
177Lu-iPSMA-RGD potential as a dual therapeutic
radiopharmaceutical.
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Introduction
The prostate specific membrane antigen (PSMA) is
expressed in normal prostate epithelial cells but is over-
expressed in 95% of metastatic prostate cancers (mPCa)
[1]. That is why the PSMA protein is an appropriate
molecular target for imaging and radiotherapy of mPCa
using specific radiopharmaceuticals [2, 3]. However,
PSMA is a multifunctional protein, as it can act as an
internalization receptor, as a nutrient absorption enzyme, or
as a peptidase involved in signal transduction in epithelial
cells and cell migration [4]. Thus, radiopharmaceuticals
based on PSMA inhibitors (iPSMA) can also be used in
other types of neoplasia different than mPCa, such as dif-
ferentiated thyroid cancer, gliomas, metastatic breast can-
cer, and osteosarcomas, among others [5–8].
Radiopeptides based on the Arg-Gly-Asp (RGD)
sequence show high affinity and selectivity for the a(v)b(3)
integrins. As a result, these peptides are useful for targeting
tumors due to the overexpression of integrins in the tumor
neovasculature and lung carcinoma, neuroblastoma,
glioblastoma, osteosarcoma, melanoma, and breast cancer
tumor cells [9, 10].
The research on new heterobivalent radiopharmaceuti-
cals that interact with two different targets on tumor cells is
a strategy for the enhancement of tumor imaging and
therapy [11–13]. Therefore, a heterobivalent conjugate of
iPSMA and RGD is expected to improve the recognition of
cancer cells positive for PSMA and a(v)b(3) integrins.
The aim of this study was to synthesize the Glu-CO-Lys-
Nal-Cys(cRGDfK(MP))- DOTA-177Lu (177Lu-iPSMA-
RGD) heterobivalent radioconjugate, as well as to assess its
in vitro potential to target C6 and U87MG cells overex-
pressing PSMA and a(v)b(3) integrins.
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Experimental
Synthesis of iPSMA-RGD
The iPSMA-RGD (((5-(2-(3-((1-(4-((4-((2S,5S,11S,14R)-
14-benzyl-11-(carboxymethyl)-5-(3-guanidinopropyl)-3,6,9,
12,15-pentaoxo-1,4,7,10,13-pentaazacyclo-pentadecan-2-
yl) butyl)amino)-4-oxobutyl)-2,5-dioxopyrrolidin-3-yl)thio)-
2-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodode-
can-1-yl)acetamido)propanamido)-3-(naphthalen-2-yl) pro-
panamido)-1-carboxypentyl)carbamoyl)glutamic acid) (MW
1775.37 g/mol) peptide (Fig. 1A) was designed at ININ
(Instituto Nacional de Investigaciones Nucleares, Mexico)
and synthesized with the support of Ontores Biotechnology
Co., Ltd (Zhejiang, China). Briefly, the Glu-CO-Lys
sequence was first obtained as previously reported [2]. The
peptide synthesis continued by addition of Fmoc-b-naph-
thyl alanine, Fmoc-cysteine(tBu) and DOTA (1,4,7,10-te-
traazacyclododecane-N, N0, N00, N000-tetraacetic acid) to
form the Glu-CO-Lys-Nal-Cys-DOTA sequence following
the standard solid-phase peptide synthesis protocols (SPPS)
[14]. The cyclo(Arg-Gly-Asp-DPhe-Lys(maleimidepropi-
onyl)) (cRGDfK(MP)) was synthesized as reported else-
where [15], with the difference being the use of D-Phe
instead of D-Tyr. Finally, MP from the cRGDfK(MP)
molecule was used as the crosslinking site to react with the
cysteine sulfhydryl group of Glu-CO-Lys-Nal-Cys-DOTA
in order to obtain the Glu-CO-Lys-Nal-
Cys(cRGDfK(MP))-DOTA conjugate (iPSMA-RGD)
(Fig. 1). The molecular structure was characterized by IR
(ATR-FTIR), mass (MALDI as ionization technique) [m/z
[MALDI ? 2H]2? = 888.6, [M ? H] ? (calc. 887.6)]
and UV spectroscopies. The chemical purity was[ 98%,
as determined by reversed phase HPLC (RP-HPLC)
(Fig. 1). The peptide eluted at tR = 9.14 min from an
analytical HPLC column, using a water/acetonitrile gradi-
ent containing 0.1 and 0.08% TFA from 95/5 to 10/90 in
30 min at a flow rate of 1 mL/min (room temperature).
Labeling of iPSMA-RGD with Lu-177
To 100 lL of a solution of iPSMA-RGD (0.5 mg in 1 mL
of 0.2 M acetate buffer, pH 5), 50 lL (740 MBq) of
177LuCl3 ([ 3 TBq/mg, EndolucinBeta
, ITG, Germany)
were added. The mixture was placed in a block heater at
95 C for 30 min. The final solution was diluted to 1 mL
with a solution of ascorbic acid (10 mg/mL). For com-
parative studies, the DOTA-cyclo-RGDfK (Pichem, Aus-
tria) synthetized as previously reported [10] and DOTA-
PSMA-617 (ABX, Germany) were also radiolabeled under
the same procedure.
Radiochemical purity was evaluated on a reversed-phase
high-performance liquid chromatography (HPLC) system
(Waters, USA) equipped with UV and radioactivity
Fig. 1 A Schematic structure of the synthesized iPSMA-RGD and its chemical characterization by B IR (ATR-FTIR), C mass (MALDI as
ionization technique), D UV–Vis spectroscopies and E Reversed-phase HPLC analysis
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detectors. Analyses were performed using an analytical
C18 column (lBondapak 5 lm, 3.9 9 300 mm2) under a
linear gradient of water/acetonitrile containing 0.1% of
TFA from 98/5 to 2/90 in 30 min at a flow rate of 1 mL/
min. The retention time for 177LuCl3 was 3.6 ± 0.3 and
15.6 ± 0.3 min, 14.1 ± 0.3 and 15.3 ± 0.3 min for 177Lu-
iPSMA-RGD, 177Lu-DOTA-cyclo-RGDfK (177Lu-RGD)
and 177Lu-DOTA-PSMA-617 (177Lu-iPSMA),
respectively.
Serum stability
For the stability evaluation of the radiopeptides in serum,
an analytical size-exclusion HPLC column (ProteinPak
300SW Waters) at a 1 mL/min flow rate and 0.01 M PBS
as eluent was used. 177Lu-iPSMA-RGD was incubated with
2 mL of diluted (1:10) human serum at 37 C. Samples
(30 lL) were taken at different times (from 30 min to
24 h) for radio-HPLC analysis.
In vitro cell studies
Cell culture
C6 (RGD-positive) rat brain glioma cells (ATCC CCL-
107TM), U87MG (RGD-positive) human primary
glioblastoma cell line (ATCC HTB-14TM) and EA.hy926
endothelial cells (ATCC CRL-2922TM) were originally
obtained from ATCC (USA). The cells were routinely
grown at 37 C in an incubator with humidified air (85%
humidity), 5% CO2 and cultured in Roswell Park Memorial
Institute Medium (RPMI, Sigma-Aldrich Co.), supple-
mented with antibiotics (100 lg/mL streptomycin and
100 U/mL penicillin) and10% fetal bovine serum.
Cell binding affinity
177Lu-iPSMA-RGD binding affinity was determined by a
competitive cell binding assay. Briefly, C6 or U87MG cells
(1 9 105 per well) were incubated at 37 C in 96-well cell
culture plates for 24 h. Then, cells were incubated at 37 C
for 1 h with ‘‘cold’’ peptides (iPSMA and/or RGD) at 8
different concentrations (from 10,000 to 0.01 nM, 30 lL/
well, n = 3) in the presence of a constant concentration of
177Lu-iPSMA-RGD (0.2 nM, 100 lL, 10 kBq). After
incubation, the supernatant was removed, and the cells
were washed three times with cold binding buffer (25 mM
Tris–HCl, 1 mM CaCl2, 150 mM NaCl, 0.1% bovine
serum albumin, pH 7.4). The radioactivity of each well was
counted in a gamma NaI(Tl) detector (NML Inc., USA),
which represented the cell-bound activity. The initial
activity of each treatment was determined by the previous
preparation of a standard representing 100%. The 50%
inhibitory concentration (IC50) was calculated by fitting the
competitive binding curves using a nonlinear regression
analysis (Origin8 Software). The same procedure was
performed to determine IC50 values for
177Lu-iPSMA and
177Lu-RGD.
Saturation assay
C6 or U87MG cells (8 9 104 per well) were incubated in
48-well cell culture plates for 24 h. Then, cells were
incubated at 4 C for 1 h with 177Lu-iPSMA-RGD at eight
different concentrations (from 1000 to 0.01 nM, 120 lL/
well plus 30 lL of binding buffer, n = 3). The non-specific
binding was determined in parallel by addition of 30 lL of
the non-radiolabeled analog (2 lM 176Lu-iPSMA-RGD,
prepared by using 82.8% enriched 176Lu, Isoflex, USA)
instead of the 30 lL of the binding buffer. After incuba-
tion, the supernatant was removed, the cells were washed
three times with 100 lL cold binding buffer, and the
radioactivity of the total withdrawn volume was counted in
a gamma NaI(Tl) detector (NML Inc., USA), which rep-
resented the non-cell-bound activity. The initial radioac-
tivity of each treatment was determined by the previous
preparation of standards representing 100%. The cell
bound radioactivity corresponds to the activity measure-
ment of the cells collected with 1 M NaOH. Specific
binding was calculated as the difference between total
binding and non-specific binding. Bmax and Kd were
determined by nonlinear regression analysis (GraphPad
Prism software). The same procedure was followed to
calculate the Bmax and Kd values for
177Lu-iPSMA and
177Lu-RGD.
Cell uptake
U87MG or C6 cells were harvested and diluted in fresh
medium (1 9 105 cells/well, 0.5 mL) to then be seeded in
48-well tissue culture plates. After 24 h, the medium was
removed, and the cells were incubated with a 25 nM
solution of each treatment (177Lu-iPSMA-RGD, 177Lu-
iPSMA or 177Lu-RGD, 30 lL/well, 100 lL of phosphate-
buffered saline) for 45 min at 37 C. Then, two rinses were
performed with one mL of ice-cold phosphate-buffered
saline (PBS). The cells were washed twice with 0.5 mL of
1 M NaOH (fraction of cell uptake and radiotracer inter-
nalization). Radioactivity was measured in a NaI(Tl)
detector (NML Inc. USA). The initial activity of each
treatment was taken to represent 100%. In parallel, the non-
specific binding was determined using 250 lM of iPSMA-
RGD, PSMA-617 or cRGDfK, which blocked cell
receptors.
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Cell viability assay
The effect of 177Lu-iPSMA-RGD, 177Lu-iPSMA or 177Lu-
RGD treatments on cell viability was assessed by the
mitochondrial dehydrogenase activity in living C6 or
U87MG cells by using the XTT (2, 3-bis[2-Methoxy-4-
nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner
salt; 0.1 mg/mL) assay kit (Roche, Germany). Briefly, C6
cells were seeded in 96-well microtiter plates (8 9 103 -
cells/well) and incubated overnight to allow cell attach-
ment. The growth medium was removed, and the cells were
incubated for 4 h with approximately 2 kBq/cell of each
treatment (200 lL). The viability after exposure to the
treatment was evaluated 24 h and 48 h (37 C, 5% CO2,
and 85% humidity). The cell proliferation percentage in
each well was evaluated by the spectrophotometric mea-
surement of cell viability (absorbance of the orange solu-
tion) at 450 nm in a microplate absorbance reader
(EpochTM, BioTek Instruments, USA). The untreated cell
absorbance was considered as 100% viability.
Western blot (inhibition of VEGF signaling)
After a serum fasting overnight, EA.hy926 endothelial
cells were exposed during 3 h to 200 lM CoCl2 (hypoxia-
like conditions). Then cells were treated with ‘‘cold’’
iPSMA or iPSMA-RGD for 5 min in the presence of
serum. Culture medium with and without serum were used
as positive and negative control, respectively. Cells were
then lysed (HEPES 50 mM, NaCl 250 mM, EDTA 5 mM,
NaF 10 mM, Nonidet P-40 0.1%, b glycerophosphate
50 mM, Na3VO41 mM, pH 7.4). Proteins were separated
by SDS-PAGE 10%, transferred to a Hy-bond ECL nitro-
cellulose membrane (Amersham) and blocked for 1 h at
room temperature (skim milk 5% in TBS-tween 0.05%).
Membranes were incubated overnight at 4 C in the pres-
ence of the rabbit monoclonal antibody anti-pVEGFR2
(Cell Signaling Technology, D5B11, 1:2000 in TBS-T
0.05% ? 1% BSA), which identifies phosphorylated
VEGFR2 in Y1175, followed by incubation with the sec-
ondary antibody HRP-goat anti-rabbit (Zymed, 65–6120)
1:10,000 in TBS-T 0.05% for 1 h at room temperature.
Load control was evaluated with actin detection (goat
polyclonal anti-actin (Santa Cruz, sc-1616) 1:3000 in TBS-
T 0.05 ? 3% skim milk overnight at 4 C, followed by
incubation with secondary antibody HRP-rabbit anti-goat
(Thermo, 31210) 1:30,000 in TBS-T 0.05% for 1 h at room
temperature. The proteins were visualized by using the
ECL-Plus western blotting detection system (GE Health-
care, UK), using the Bio-Rad ChemiDoc XRS detection
system (Bio-Rad Hercules, CA).
Statistical analysis
Data were expressed as mean ± SD of the results of three
independent replicas of each assayed condition. Differ-
ences between treatments of the unblocked and blocked
receptors were evaluated with Student’s t test. Two-way
analysis of variance (ANOVA) was used to assess the
effects of the different treatments on viability.
Results and discussion
Synthesis and chemical characterization
The schematic structure of iPSMA-RGD and its spectroscopic
characterization (IR, masses, UV–Vis and HPLC) are shown
in Fig. 1. The IR spectrum (Fig. 1B) shows the vibrations
from amide I, II and III of the peptide at 1646, 1534 and
1470–1160 cm-1, respectively. Bands at 1239 and
1161 cm-1, due to C–N–C vibrations from the DOTA and
RGD cycles, are observed. Characteristic bands of the C–N
stretch vibration from urea at 1440 cm-1, related to the
iPSMA molecule, is also observed (Fig. 1B). The mass
spectrum (Fig. 1C) shows the molecular ion [M?2H]2? at m/
z = 888.6 and the ion [M?3H]3? at m/z = 592.9. Other
signals corresponding to the iPSMA-RGD structure as result
of fragmentation pattern of the molecule (ionized fragments)
are observed at 535.2 (CO-b-naphtyl-Ala-Lys-Urea-Glu),
728.9 [cRGDfK(MP)) and 815.0 (cRGDfK(MP-S-CH3)]m/z.
The UV spectrum (Fig. 1D) of iPSMA-RGD conjugate shows
a band at 269 nm, which is a displacement of approximately
8 nm from the iPSMA and cRGDfK UV-spectra, which
showed a characteristic band at 277 ± 0.5 nm. The HPLC
chromatogram indicated a chemical purity of[ 98%
(Fig. 1E). The radiochemical purities of 177Lu-iPSMA-RGD
was 98.8 ± 1.0%, as obtained by reversed-phase HPLC
(n[ 12). 177Lu-iPSMA and 177Lu-RGD also showed radio-
chemical purities of[ 98%.
In vitro evaluation and cell studies
177Lu-iPSMA-RGD was highly stable in human serum
since, after 1 and 24 h, only 2 and 6% of the radiophar-
maceutical was bound to plasma proteins (shift to higher
molecular weight), respectively. Only negligible peaks
were eluted at lower molecular weights, indicating that
177Lu-iPSMA-RGD is not significantly catabolized in
serum and therefore has suitable metabolic stability. These
results agree with previous studies in which the average
fraction of intact radio-RGD or radio-iPSMA (68Ga-
DOTA-RGD and 111In-DOTA-RGD or 99mTc-EDDA/
HYNIC-iPSMA) in blood is over 85% [2, 16].
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Competition and saturation binding assays were con-
ducted to determine the affinity of 177Lu-iPSMA-RGD by
calculating the IC50, Kd, and Bmax values. As can be
observed in Figs. 2 and 3 and Table 1, 177Lu-iPSMA-RGD
was specifically recognized by PSMA and a(v)b(3) inte-
grins with a suitable affinity (U87MG cells:
IC50 = 1.05 nM, Kd = 5.81 nM, Bmax = 0.32 nM) to be
used as a potential radiotherapeutic radiopharmaceutical.
Furthermore, the heterobivalent conjugate also demon-
strated the ability to affect significantly (p\ 0.01) U87MG
and C6 cell viability (Fig. 4). However, 177Lu-iPSMA and
177Lu-RGD were found to have a slightly greater affinity
for PSMA and integrins than 177Lu-iPSMA-RGD (Table 1,
Fig. 2 and Fig. 3), although with IC50, Kd and Bmax values
in the same order of magnitude for all radiopharmaceuti-
cals. That means that all of them could be useful in targeted
radionuclide therapy.
The ANOVA results also indicated that all radioligands
had a significant effect (p\ 0.01) on U87MG and C6 cell
viability without statistically significant difference among
the three treatments (Fig. 4). Nevertheless, a greater effect
on viability was observed in the U87MG cells (* 30% at
48 h) with regard to C6 (* 80% at 48 h). Of concern is the
apparent non-specific cell uptake of radiopharmaceuticals
in C6 cells (Fig. 3), in which blocked cells showed a sig-
nificant radioactivity uptake. However, the specific binding
for all radioligands to C6 cells is evident in the affinity
assay results (Fig. 2 and Table 1). This fact could be
explained based on the concentration of unlabeled peptides
Fig. 2 Competition assay of a constant concentration of 177Lu-iPSMA-RGD, 177Lu-iPSMA, and 177Lu-RGD with ‘‘cold’’ peptides (iPSMA and/
or RGD) at 8 different concentrations (from 10,000 to 0.01 nM in A C6 and B U87MG cells
Fig. 3 Specific uptake of
177Lu-iPSMA-RGD, 177Lu-
iPSMA, and 177Lu-RGD in C6
and U87MG cells. Cells with
blocked receptors were co-
incubated with an excess of the
respective ‘‘cold’’ peptides
(iPSMA-RGD, iPSMA or RGD)
Table 1 Affinity of 177Lu-iPSMA-RGD, 177Lu-iPSMA, and 177Lu-
RGD, as determined by the saturation assay
Radiotracer C6 cells U87MG cells
Kd (nM) Bmax (nM) Kd (nM) Bmax (nM)
177Lu-RGD 4.54 0.219 4.31 0.366
177Lu-iPSMA 3.89 0.067 3.84 0.383
177Lu-iPSMA-RGD 4.60 0.284 5.81 0.321
J Radioanal Nucl Chem (2017) 314:2201–2207 2205
123
used for the competition/blocking receptors since for the
cell uptake test a concentration of 250 lM ‘‘cold’’ peptide
was used, while for saturation assays it was two orders of
magnitude lower (2 lM). Therefore, the high levels of
‘‘cold’’ peptide possibly trigger C6 cell mechanisms that
promote 177Lu-peptide internalization, instead of a receptor
blocking effect.
Affinity, cell uptake, and viability assays indicated that
177Lu-iPSMA-RGD was not able to concomitantly recognize
two receptors on the cell surface or to improve the cell uptake
concerning 177Lu-iPSMA or 177Lu-RGD monomers, as other
authors have reported for heterobivalent molecules [11–13].
However, the intrinsic heterogenicity of human tumors, as
well as changes in phenotype during disease progression,
including the different level expression of cell surface
receptors, is well-known. Therefore, the use of 177Lu-
iPSMA-RGD as a dual targeting radiopharmaceutical may
improve detection sensitivity and therefore, absorbed radi-
ation doses during therapy. Furthermore, heterobivalent
molecules may display synergic properties such as
enhancement of the antiangiogenic potential. As can be seen
in Fig. 5, on hypoxic-like condition iPSMA-RGD was able
to inhibit the phosphorylation of VEGFR2 (low pVEGFR2
value) behavior that was not observed with the iPSMA
treatment. Therefore, the iPSMA-RGD heterodimeric com-
pound showed suitable properties to act over tumor vascu-
lature as an antiangiogenic molecule [17, 18].
Considering that avb3 integrin and PSMA are overex-
pressed in the neovasculature of primary tumors and in
metastatic lesions, a synergistic or dual recognition in vivo
effect of the 177Lu-iPSMA-RGD by different solid tumors
is expected.
Conclusions
177Lu-iPSMA-RGD was prepared with radiochemical
purities of[ 98%, as a stable and specific radiopharma-
ceutical to target PSMA and a(v) b(3) integrins, and with
suitable affinity to be used as a radiotherapeutic agent. The
iPSMA-RGD heterobivalent molecule showed potential to
inhibit the VEGFR2 signaling. Nevertheless, preclinical
studies are necessary to evaluate and determine the thera-
peutic potential of 177Lu-iPSMA-RGD.
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